{"id":53370,"date":"2025-05-16T14:06:36","date_gmt":"2025-05-16T21:06:36","guid":{"rendered":"https:\/\/www.salk.edu\/?page_id=53370"},"modified":"2026-03-05T11:30:16","modified_gmt":"2026-03-05T19:30:16","slug":"salk-board-of-trustees","status":"publish","type":"page","link":"https:\/\/www.salk.edu\/de\/people\/salk-board-of-trustees\/","title":{"rendered":"Kuratorium"},"content":{"rendered":"<style>\r\n\t.centered-bio-wrapper {\r\n\t\tdisplay: flex;\r\n\t\tjustify-content: center;\r\n\t\tmargin-bottom: 20px;\r\n\t}\r\n\r\n\t.centered-bio {\r\n\t\twidth: 48%; \/* Same width as the columns *\/\r\n\t}\r\n\r\n\t\t.bot-title {\r\n\t\t\tfont-weight: bold;\r\n\t\t}\r\n\r\n\t.accordion-container {\r\n\t\tdisplay: grid;\r\n\t\tgrid-template-columns: 1fr 1fr; \/* Two columns *\/\r\n\t\tgap: 20px;\r\n\t}\r\n\t\r\n    .accordion {\r\n       \r\n        border: 1px solid #ddd;\r\n        margin-bottom: 10px;\r\n        cursor: pointer;\r\n        transition: background-color 0.3s;\r\n    }\r\n\r\n    .accordion:hover {\r\n        background-color: #fff;\r\n    }\r\n\r\n    .accordion-header {\r\n        padding: 15px;\r\n        display: flex;\r\n        justify-content: space-between;\r\n        align-items: center;\r\n    }\r\n\r\n    .accordion-header h3 {\r\n        margin: 0;\r\n        font-size: 1.1em;\r\n        color: #333;\r\n    }\r\n\r\n    .accordion-header img {\r\n        width: 50px;\r\n        height: 50px;\r\n        border-radius: 50%;\r\n        object-fit: cover;\r\n        margin-right: 15px;\r\n    }\r\n\r\n    .accordion-content {\r\n        display: none;\r\n        padding: 20px;\r\n        border-top: 1px solid #ddd;\r\n        background-color: #f8f8f8;\r\n        overflow: hidden;\r\n        transition: max-height 0.3s ease;\r\n    }\r\n\r\n    .accordion-content img {\r\n        float: left;\r\n        width: 150px;\r\n        height: 200px;\r\n        object-fit: cover;\r\n        margin-right: 20px;\r\n    }\r\n\r\n    .accordion-content p {\r\n       \r\n        color: #555;\r\n    }\r\n\r\n    .accordion-content::after {\r\n        content: \"\";\r\n        display: table;\r\n        clear: both;\r\n    }\r\n\r\n    .toggle-icon {\r\n        font-size: 1.5em;\r\n        color: #333;\r\n        transition: transform 0.3s;\r\n    }\r\n\r\n    .active .toggle-icon {\r\n        transform: rotate(180deg);\r\n    }\r\n<\/style>\r\n\r\n\r\n<p>The Board of Trustees is composed of proven leaders from the world&#8217;s business and non-profit communities who bring a range of skills and perspectives to the Institute. They are committed to science, innovation, high-quality research and supporting the Institute&#8217;s mission. Trustees are charged with monitoring Institute operations to ensure the organization fulfills its scientific and training efforts, while operating in a financially responsible manner.\r\n<\/p>\r\n\r\n\r\n<!-- Chair -->                                                \r\n<div class=\"row\">\r\n<div class=\"col-12 centered-bio-wrapper\">\r\n<div class=\"accordion centered-bio\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Marna C. Whittington, PhD <span>(Chair)<\/span><\/h2>\r\n<p class=\"bot-title\">(Retired) Chief Executive Officer<\/p>\r\n<span style=\"font-weight: normal;\">Allianz Global Investors Capital<br \/>\r\nDelaware<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Marna-BOT.png\" alt=\"Marna C. Whittington\">\r\n\r\n<p>Marna C. Whittington has served on Salk\u2019s Board of Trustees since 2005. She is currently chair of the Board and chair of the Development Committee. She was the CEO of Allianz Global Investors Capital from 2001 until her retirement in January 2012. She also served as COO of Allianz Global Investors, the parent company of Allianz Global Investors Capital. Prior to that, she was managing director and COO of Morgan Stanley Asset Management.<\/p>\r\n\r\n<p>Whittington started in the investment management industry in 1992 when she joined Philadelphia-based Miller Anderson &amp; Sherrerd. Previously, she was EVP and CFO of the University of Pennsylvania and, earlier, Secretary of Finance for the State of Delaware. Whittington currently serves on the boards of Tower Hill School, the Philadelphia Contributionship (a company founded by Benjamin Franklin), Phillips 66, Oaktree Capital Management L.P., and Ocugen.<\/p>\r\n\r\n<p>Whittington earned her BA in mathematics and PhD from the University of Pittsburgh.<\/p>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<!-- End Chair -->\r\n\r\n<!-- Vice Chair -->                                                \r\n<div class=\"row\">\r\n<div class=\"col-12 centered-bio-wrapper\">\r\n<div class=\"accordion centered-bio\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Terry Rosen, PhD (Vice Chair)<\/h2>\r\n<p class=\"bot-title\">CEO and Chair<br>\r\n<span style=\"font-weight: normal;\">Arcus Biosciences<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Rosen-150x200-1.jpg\" alt=\"Terry Rosen\">\r\n\r\n<p>Terry Rosen has served on Salk\u2019s Board of Trustees since 2015. He is currently vice chair of the Board. He has more than 30 years of experience in drug discovery and development in the biotechnology and pharmaceutical industries. In 2015, he co-founded Arcus Biosciences, focusing on cancer treatments that block tumor-induced immunosuppression. He is currently the CEO and Chairman of Arcus.<\/p>\r\n\r\n<p>Before that, he was co-founder and CEO of Flexus Biosciences, which developed small-molecule drugs to reverse tumor immunosuppression; Flexus was acquired by Bristol-Myers Squibb in 2015 for $1.25 billion.<\/p>\r\n\r\n<p>Rosen previously served as vice president of Therapeutic Discovery at Amgen, overseeing the creation of a 550+ staff organization responsible for all drug discovery efforts. He joined Amgen in 2004 with the acquisition of Tularik, where he held several executive roles, including executive vice president of Operations.<\/p>\r\n\r\n<p>Earlier in his career, he held positions at Pfizer and Abbott Laboratories. Currently, Rosen serves on the Scientific Advisory Board of the University of Michigan Life Sciences Institute, as well as on the boards of the UC Berkeley Foundation and the California Life Sciences Association.<\/p>\r\n\r\n<p>Rosen earned his BS in chemistry at the University of Michigan, Ann Arbor, and his PhD in organic chemistry at the University of California, Berkeley.<\/p>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<!-- End Vice Chair -->\r\n\r\n<div class=\"accordion-container\">\r\n\r\n<!-- Person 1 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Janelle Ayres, PhD<\/h2>\r\n<p class=\"bot-title\">Professor<br>\r\n<span style=\"font-weight: normal;\">Salk Institute Legacy Chair<br>\r\nSalk Institute<br>\r\nHoward Hughes Medical Institute Investigator<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Ayres-150x200-1.jpg\" alt=\"Janelle Ayres\">\r\n\r\n<p>Janelle Ayres is a professor, head of the Molecular and Systems Physiology Laboratory, a member of both the Gene Expression Laboratory and the NOMIS Center for Immunobiology and Microbial Pathogenesis, and holder of the Salk Institute Legacy Chair at the Salk Institute, as well as a Howard Hughes Medical Institute investigator.<\/p>\r\n\r\n<p>In her research, Ayres aims to shift the paradigm in infectious disease research from an exclusive focus on pathogen eradication to a broader understanding of how a host can adapt to infections to maintain health and promote survival with cooperative defense mechanisms that protect from disease, without compromising pathogen fitness. By doing so, this research aims to provide a solution for the global crisis of antibiotic resistance.<\/p>\r\n\r\n<p>Ayres has been recognized with numerous awards, including a National Institutes of Health Pioneer Award and a Blavatnik National Award for Young Scientists. She earned her BA in molecular and cell biology at the University of California, Berkeley, and her PhD in microbiology and immunology at Stanford University before conducting her postdoctoral training at the University of California, Berkeley.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 1 -->\r\n\t\r\n\t\r\n<!-- Person 2 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Wolfgang Busch, PhD<\/h2>\r\n<p class=\"bot-title\">Professor<br>\r\n<span style=\"font-weight: normal;\">Hess Chair in Plant Science<br>\r\nSalk Institute<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Busch-150x200-1.jpg\" alt=\"Wolfgang Busch\">\r\n\r\n<p>Wolfgang Busch is a professor, executive director of the Harnessing Plants Initiative, and Hess Chair in Plant Science at the Salk Institute.<\/p>\r\n\r\n<p>He is a plant biologist who studies the genes and molecular mechanisms that determine how a plant\u2019s genetic information interacts with the environment and is translated by molecular, cellular, and physiological networks to shape plant root growth. His research could help grow more resilient food sources\u2014an increasingly urgent problem in the face of the planet\u2019s shifting climate and increasing population\u2014and help develop root systems that can be utilized on a large scale to store carbon in the soil that was captured by above-ground plant parts from atmospheric carbon dioxide.<\/p>\r\n\r\n<p>Busch was recognized with the Society for Experimental Biology President&#8217;s Medal. He earned his MS in biology at the University of T\u00fcbingen, Germany, and his PhD in biology at the Max Planck Institute for Developmental Biology and the University of T\u00fcbingen.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 2 -->\r\n\t\r\n\t\r\n<!-- Person 3 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>David Dolby<\/h2>\r\n<p class=\"bot-title\">CEO<br>\r\n<span style=\"font-weight: normal;\">Dolby Family Ventures<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Dolby-150x200-1.jpg\" alt=\"David Dolby\">\r\n\r\n<p>David Dolby has served on Salk\u2019s Board of Trustees since 2019. He is a San Francisco-based investor and philanthropist dedicated to advancing science, technology, and media. Committed to honoring the legacy of his father, Ray Dolby, he supports innovative cultures focused on differentiated signal processing to address real-world challenges.<\/p>\r\n\r\n<p>As managing director of Dolby Family Ventures, Dolby oversees a diverse portfolio of more than 40 venture investments, including Internet technology, semiconductors, aerospace, and Alzheimer\u2019s drug discovery. He also serves as a director of Dolby Laboratories and Cogstate Limited and as CFO of the Ray and Dagmar Dolby Family Fund.<\/p>\r\n\r\n<p>Beyond his corporate roles, Dolby is an active board member and chair of the impact committee for Tipping Point Community, where he addresses poverty in the Bay Area. He also contributes to the Academy Museum of Motion Pictures, focusing on the technical aspects of filmmaking.<\/p>\r\n\r\n<p>He earned his BS from Duke University Pratt School of Engineering and his MBA from Stanford Graduate School of Business.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 3 -->\r\n\t\r\n\t\r\n<!-- Person 4 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Fred Dotzler<\/h2>\r\n<p class=\"bot-title\">Managing Director<br>\r\n<span style=\"font-weight: normal;\">De Novo Ventures<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<!--<span class=\"toggle-icon\">\u25bc<\/span>-->\r\n<\/div>\r\n\r\n<!--<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Dotzler_edit-1.jpg\" alt=\"Fred Dotzler\">\r\n\r\n<p>Fred Dotzler has served on Salk\u2019s Board of Trustees since 2009. He is the managing director and co-founder of De Novo Ventures, bringing 35 years of venture capital experience and 13 years of corporate operating expertise. Before co-founding De Novo, Dotzler served as managing general partner at Medicus Venture Partners, which he established in 1989. Prior to his venture capital career, he held executive roles in finance, marketing, and business development at prominent companies, including Searle and IBM.<\/p>\r\n\r\n<p>Dotzler serves on advisory boards for The Journal of Private Equity and The Gruter Institute and is a trustee of the Santa Fe Institute.<\/p>\r\n\r\n<p> He earned an MBA from the University of Chicago, a Master\u2019s equivalent in economics from the University of Louvain, Belgium, and a BS in engineering from Iowa State University, where he received the Professional Achievement Citation in Engineering in 2000.<\/p>\r\n<\/div>-->\r\n<\/div>\r\n<!-- End Person 4 -->\r\n\t\r\n\t\r\n<!-- Person 5 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Jay T. Flatley<\/h2>\r\n<p class=\"bot-title\">(Former) CEO, Chair<br>\r\n<span style=\"font-weight: normal;\">Illumina<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Flatley-150x200-1.jpg\" alt=\"Jay T. Flatley\">\r\n\r\n<p>Jay T. Flatley has served on Salk\u2019s Board of Trustees since 2017. He served as CEO of Illumina from 1999 until mid-2016, subsequently holding the position of executive chairman until 2019 and chairman of the board until mid-2021.<\/p>\r\n\r\n<p>In August 2021, Flatley became Interim CEO of Zymergen until the company\u2019s acquisition by Ginkgo Bioworks in October 2022. He currently serves on the boards of Denali, Rivian, Iridia (Chairman), and Wellcome Leap.<\/p>\r\n\r\n<p> Previously, Flatley served as President and Chief Executive Officer of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare. As a co-founder and member of the board of directors for Molecular Dynamics, he led the company to its initial public offering and helped develop and launch over 15 major instrumentation systems. Prior to joining Molecular Dynamics, Jay was Vice President of Engineering and Strategic Planning for Plexus Computers, Executive Vice President for Manning Technologies, and held various positions at Spectra Physics.<\/p>\r\n\r\n<p>Flatley earned a BA in economics from Claremont McKenna College and both a BS and MS in industrial engineering from Stanford University.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 5 -->\r\n\t\r\n\t\r\n<!-- Person 6 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Carol Gallagher, PharmD<\/h2>\r\n<p class=\"bot-title\">(Retired) BioPharma Executive and<br>\r\nVenture Capital Investor<br>\r\n<span style=\"font-weight: normal;\">California<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Gallagher-150x200-1.jpg\" alt=\"Carol Gallagher\">\r\n\r\n<p>Carol Gallagher has served on Salk\u2019s Board of Trustees since 2022. She is currently chair of the Audit Committee. She has more than 35 years of experience in the biopharma industry, having been a CEO, a venture capital investor, and a board director.<\/p>\r\n\r\n<p>She currently serves as a director for both public and private companies. Early in her career, she held both business and drug development roles in small and large biopharma. She was CEO of Calistoga Pharmaceuticals which was acquired by Gilead in 2011. Over her career, she has been involved in various teams and boards that resulted in the development of multiple approved therapeutics. She previously served on the Sharp Healthcare Board and is currently a board member of Life Sciences Cares, a non-profit addressing poverty in San Diego.<\/p>\r\n\r\n<p>Gallagher earned her BS and PharmD from the University of Kentucky.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 6 -->\r\n\r\n\r\n<!-- Person 7 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Richard A. Heyman, PhD<\/h2>\r\n<p class=\"bot-title\">Chair of the Board<br>\r\n<span style=\"font-weight: normal;\">ORIC Pharmaceuticals<br \/>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/rich-heyman.png\" alt=\"Richard A. Heyman\">\r\n\r\n<p>Richard A. Heyman, PhD, has served on Salk\u2019s Board of Trustees since 2015. He is currently chair of the Nominating &amp; Governance Committee. He is a scientist and entrepreneur with more than 25 years of experience in the biotech and life science field. Recently, Heyman co-founded and serves as Chairman of Architect Therapeutics, a small molecule drug discovery company applying novel chemical editing technologies to expand the druggable space.<\/p>\r\n\r\n<p>Previously, he served as Chairman of Vividion Therapeutics, purchased by Bayer Pharma, Amunix Pharma, purchased by Sanofi and Rayze Bio purchased by BMS in 2023.  He is the co-founder and Chairman of ORIC Pharmaceuticals and serves as Chairman of Enliven Therapeutics and PMV Pharma.  Earlier in his career, Heyman was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, which focused on therapies for hormone dependent cancers; J&amp;J purchased Aragon in 2013 and Genentech\/Roche purchased Seragon one year later.  He has been involved in the discovery and development of multiple FDA approved therapies, including the prostate cancer drug, Erleada.  Heyman is a Venture\/Science Partner for Arch Ventures and Nextech Invest.  Outside his corporate experience, Heyman is Vice Chair of the Board at the Salk Institute, BOD member at the UCSD Moores Cancer Center and a founding member of both Life Science Cares, San Diego and Curebound.  He has won numerous awards including E&amp;Y San Diego Regional Entrepreneur of the Year, Connect Hall of Fame Award, the UCSD Rell Sun Award and Endocrine Society Outstanding Innovation Award.  Heyman is the author or inventor on more than 125 publications and patents.<\/p>\r\n<\/div>\r\n<\/div> \r\n<!-- End Person 7 -->\r\n\t\r\n\t\r\n<!-- Person 8 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Lyn Hutton<\/h2>\r\n<p class=\"bot-title\">(Retired) Financial and Investment Manager<br>\r\n<span style=\"font-weight: normal;\">California<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Hutton-150x200-1.jpg\" alt=\"Lyn Hutton\">\r\n\r\n<p>Lyn Hutton has served on Salk\u2019s Board of Trustees since 2021. She is currently co-chair of the Investment Committee. She has nearly 40 years of experience in financial and investment management for nonprofit organizations. Before retiring in 2015, she served as the managing director and chief operating officer of Prager &amp; Co., LLC.<\/p>\r\n\r\n<p>Before joining Prager, Hutton was the chief investment officer of Commonfund, where she chaired the firm\u2019s Investment Committee and previously served as the chair of its board of trustees. Previously, she served as the vice president and chief financial &amp; investment officer of the John D. and Catherine T. MacArthur Foundation, managing the Foundation\u2019s (then) $4 billion investment portfolio. Before MacArthur, Hutton served as vice president, chief financial officer, and treasurer at Dartmouth College. Before Dartmouth, she was senior vice president of Finance and Administration for the University of Southern California and was its treasurer.<\/p>\r\n\r\n<p>Hutton is a recipient of NACUBO\u2019s Rodney Adams Award and, in 2010, was awarded Institutional Investor Magazine\u2019s Investor Lifetime Achievement Award. She earned her BS in business administration from the University of Southern California.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 8 -->\r\n\t\r\n\r\n<!-- Person 9 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Amy Jacobs<\/h2>\r\n<p class=\"bot-title\">Philanthropist<br>\r\n<span style=\"font-weight: normal;\">California<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Jacobs-150x200-1.jpg\" alt=\"Amy Jacobs\">\r\n\r\n<p>Amy Jacobs has served on Salk\u2019s Board of Trustees since 2024. Since moving to San Diego in 2011, philanthropist she has supported local Jewish organizations, the Jacobs Cushman San Diego Food Bank, the San Diego Zoo Wildlife Alliance, and housing and homelessness initiatives in San Diego.<\/p>\r\n\r\n<p>Jacobs and her husband, Adam, are parents to two young children. The driving force behind their philanthropy is based on \u201ctikkun olam,\u201d a Hebrew term for \u201cworld repair,\u201d the idea that we are all responsible for leaving the world a better place than we found it.<\/p>\r\n\r\n<p>Jacobs is a member of the Pauline Foster Women\u2019s Leadership Institute and a former member of ForwardGlobal (formerly the Philanthropy Workshop). She earned her BS in biological science from the University of Alberta, Canada.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 9 -->\r\n\t\r\n\r\n<!-- Person 10 -->\t\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Sanjay K. Jha, PhD<\/h2>\r\n<p class=\"bot-title\">Partner<br>\r\n<span style=\"font-weight: normal;\">SanTuri Ventures<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2026\/03\/26-bot-jha.png\" alt=\"Sanjay K. Jha\">\r\n\r\n<p>Sanjay K. Jha has served on Salk\u2019s Board of Trustees since 2013. He is a General Partner and serves as the Chair of the Investment Committee at SanTuri Ventures.<\/p>\r\n\r\n<p>Jha was previously CEO of GlobalFoundries and chairman and CEO of Motorola Mobility.  Prior to Motorola, he was COO of Qualcomm and president of Qualcomm CDMA Technologies. He began his Qualcomm career in 1994 as a senior engineer, leading 6 generations of mobile phone chip design and development.<\/p>\r\n\r\n<p>He holds a BS in engineering from the University of Liverpool and a doctorate in electronic and electrical engineering from the University of Strathclyde. Sanjay was inducted into the National Academy of Engineering in 2018.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 10 -->\r\n\t\r\n\t\r\n<!-- Person 11 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Gerald Joyce, MD, PhD<\/h2>\r\n<p class=\"bot-title\">President and Professor<br>\r\n<span style=\"font-weight: normal;\">Salk Institute<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Joyce-150x200-1.jpg\" alt=\"Gerald Joyce\">\r\n\r\n<p>Gerald Joyce serves as the president of the Salk Institute. In addition, he is a professor in the Jack H. Skirball Center for Chemical Biology and Proteomics. Joyce began his scientific career at Salk as a PhD student and then a postdoctoral scholar. He returned as a faculty member in 2017 and served as senior vice president and chief science officer from 2022 to 2023. His research program focuses on the development of novel RNA and DNA enzymes and their potential application in clinical diagnostics and therapeutics. His research has led to the development of the first self-replicating RNA enzyme that is capable of exponential growth and evolution.<\/p>\r\n\r\n<p>From 2014 to 2021, Joyce served as director of the Genomics Institute of the Novartis Research Foundation (GNF). He has served previously as dean of the faculty at Scripps Research and as a member of the Technology Advisory Council of BP.<\/p>\r\n\r\n<p>Joyce earned his BA from the University of Chicago and his MD and PhD from the University of California San Diego. He completed his postgraduate medical training at Mercy Hospital in San Diego and postdoctoral research training at the Salk Institute.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- Person 11 -->\r\n\t\r\n\t\r\n<!-- \r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Mark Knickrehm<\/h2>\r\n<p class=\"bot-title\">Chair and CEO<br>\r\n<span style=\"font-weight: normal;\">Gainwell Technologies<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Knickrehm-150x200-1.jpg\" alt=\"Mark Knickrehm\">\r\n\r\n<p>Mark Knickrehm has served on Salk\u2019s Board of Trustees since 2019. He is chairman and CEO of Gainwell Technologies. Previously, Knickrehm was the global group chief executive of Accenture Strategy, Accenture\u2019s consulting business, which focuses on solving clients\u2019 most pressing challenges at the intersection of business, technology, and operations\u2014helping clients\u2019 C-suite executives develop strategies to transform their organizations. He was also a member of Accenture\u2019s Global Management Committee. Prior to assuming the role, Knickrehm served as senior managing director, leading Accenture\u2019s global health industry group; he was also responsible for growth and strategy in the Health &amp; Public Services operating group.<\/p>\r\n\r\n<p>Knickrehm spent 12 years at McKinsey &amp; Company, where, as a partner, he focused on strategy, operations, and organization. He also served for two years as executive vice president, CFO, and president of international operations for Paging Network, Inc. (PageNet). Knickrehm is also on the board of Gainwell Technologies and is a board advisor to ZS Associates.<\/p>\r\n\r\n<p>Knickrehm earned his BA from Northwestern University and his MBA from the University of Chicago.<\/p>\r\n<\/div>\r\n<\/div>\r\n -->\r\n\t\r\n\t\r\n<!-- Person 12 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Benjamin H. Lewis, MD<\/h2>\r\n<p class=\"bot-title\">Professor Emeritus, Attending Physician<br>\r\n<span style=\"font-weight: normal;\">New York Presbyterian Hospital<br>\r\nNew York<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Lewis-150x200-1.jpg\" alt=\"Benjamin H. Lewis\">\r\n\r\n<p>Benjamin H. Lewis has served on Salk\u2019s Board of Trustees since 2011. He is a professor emeritus of medicine at Columbia University and an attending physician at  New York-Presbyterian Hospital.<\/p>\r\n\r\n<p>Lewis has devoted his career to the prevention of cardiovascular disease. His particular focus is on the increased use of lifestyle approaches, medical therapies, and noninvasive, nonradioactive techniques\u2014in particular, ultrasound\u2014for diagnosing and managing heart disease patients.<\/p>\r\n\r\n<p>Lewis earned his BA in biological sciences from the University of California, Berkeley and his MD from the University of California, San Francisco Medical School. He then continued his training with an internship at the University of Pennsylvania, followed by his residency at Columbia University Medical Center. After a short sojourn in Boston to complete a two-year fellowship at the Brigham and Women\u2019s Hospital, Lewis returned to Columbia-Presbyterian in 1982 and has remained with Columbia ever since.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 12 -->\r\n\t\r\n\t\r\n<!-- Person 13 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Fred Luddy<\/h2>\r\n<p class=\"bot-title\">Founder<br>\r\n<span style=\"font-weight: normal;\">ServiceNow<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2025\/05\/25-bot-luddy.jpg\" alt=\"Benjamin H. Lewis\">\r\n\r\n<p>Fred Luddy has served on Salk\u2019s Board of Trustees since 2024. He founded ServiceNow, a leading intelligent platform driving end-to-end digital transformation. Under his leadership, ServiceNow became the fastest-growing enterprise software company to achieve more than $10 billion in annual revenue organically. During his nearly 20-year tenure with ServiceNow, Luddy has held several leadership roles, including CEO from 2004 to 2011. He has served as a member of the company\u2019s board of directors since 2004, including as board chair from 2018 to 2022.<\/p>\r\n\r\n<p>Today, Luddy continues to innovate as a technology visionary, focusing on projects to revolutionize spreadsheets and improve the diagnosis and treatment of rare genetic diseases in children. A committed philanthropist, he supports numerous causes, including Indiana University, where his contributions have led to the construction and expansion of the Luddy School of Informatics, Computing, and Engineering.<\/p>\r\n\r\n<p>Luddy attended Indiana University but left before graduating to dedicate more time to programming. He has been recognized with the Ernst &amp; Young Entrepreneur of the Year Award (2011) and Indiana University\u2019s Bicentennial Medal (2020).<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 13 -->\r\n\t\r\n\t\r\n<!-- Person 14 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Corinne Mentzelopoulos<\/h2>\r\n<p class=\"bot-title\">Chairman and Chief Executive Officer<br>\r\n<span style=\"font-weight: normal;\">Ch\u00e2teau Margaux<br>\r\nFrance<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<!--<span class=\"toggle-icon\">\u25bc<\/span>-->\r\n<\/div>\r\n\r\n<!--<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Mentzelopoulos-150x200-1.jpg\" alt=\"Corinne Mentzelopoulos\">\r\n\r\n<p>Corinne Mentzelopoulos has served on Salk\u2019s Board of Trustees since 2003. She is the owner and CEO of Ch\u00e2teau Margaux, an internationally known wine estate in Bordeaux, France. She also served as vice chairman of Exor S.A., a holding company for food retail distribution and real estate. In the early 1980s, she was a financial controller for Primist\u00e8res, a holding company for the 1800 Felix Potin retail stores in Paris and also worked as an advertising manager for a major French advertising firm.<\/p>\r\n\r\n<p>Mentzelopoulos joined the Salk International Council in 1988. In 1999, she was appointed to the French Foreign Trade Council. She has served on the board of directors of the Exor Group in Luxembourg and the Soci\u00e9t\u00e9 des Industries Chimiques du Nord de la Gr\u00e8ce in Athens, Greece. Since 2009, she has been a trustee of the American University of Paris. She is a board member of The Hellenic Initiative, a philanthropic institution based in the US, and a member of the Benaki Museum International Honorary Council in Athens, Greece. In 2013, she was appointed Grand-Croix \u2018Pro-Merito Melitensi\u2019 of the Sovereign Order of Malta. Mentzelopoulos has earned the titles of Chevalier of the L\u00e9gion d\u2019Honneur and Officier of the Ordre National du M\u00e9rite for excellence in her field.<\/p>\r\n\r\n<p>Mentzelopoulous earned her BA in humanities at Paris University and MBA at the Institut D\u2019\u00e9tudes Politiques.<\/p>\r\n<\/div>-->\r\n<\/div>\r\n<!-- End Person 14 -->\r\n\t\r\n\t\r\n<!-- Person 15 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Christian Metallo, PhD<\/h2>\r\n<p class=\"bot-title\">Professor<br>\r\nDaniel and Martina Lewis Chair<br>\r\n<span style=\"font-weight: normal;\">Salk Institute<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2025\/05\/25-bot-metallo.jpg\" alt=\"Christian Metallo\">\r\n\r\n<p>Christian Metallo is a professor in Salk\u2019s Molecular and Cell Biology Laboratory and an adjunct professor of Bioengineering at UC San Diego. He is a bioengineer who studies how our body metabolizes molecules like glucose, fats, and amino acids to generate the building blocks and energy needed to perform life-sustaining tasks\u2014and how changes in metabolism contribute to disease.<\/p>\r\n\r\n<p>Metallo has made key discoveries about the metabolic pathways that drive cancer progression, peripheral neuropathy, and macular disease\u2014pathways that can be influenced through dietary manipulations or targeted therapies.<\/p>\r\n\r\n<p>Metallo earned his BS in Chemical Engineering at the University of Pennsylvania and his MS and PhD in Chemical and Biological Engineering at the University of Wisconsin-Madison. He trained as a postdoctoral researcher at MIT. He was to the AIMBE College of Fellows in 2021.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 15 -->\r\n\t\r\n\t\r\n<!-- Person 16 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Howard Newman, PhD<\/h2>\r\n<p class=\"bot-title\">Chairman and CEO<br>\r\n<span style=\"font-weight: normal;\">Pine Brook Road Partners, LLC<br>\r\nNew York<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Newman-150x200-1.jpg\" alt=\"Howard Newman\">\r\n\r\n<p>Howard Newman has served on Salk\u2019s Board of Trustees since 2002. He is chairman and CEO of Pine Brook Road Partners, LLC, which he founded in 2006.Pine Brook currently has $2.6B under management in venture capital funds that make business building and other growth equity investments, primarily in the energy and financial services industries.<\/p>\r\n\r\n<p>In addition to overseeing Pine Brook\u2019s portfolio, Newman serves on the board of the Tunisian American Enterprise Fund. He has served as a director (or designated observer) of more than 40 companies, including 18 public companies. During the term of Governor George Pataki of New York, Newman served as an advisor to Governor Pataki on energy policy. Newman is past Chairman of the Yale University Council Committee on New Haven Economic Development and the Yale Alumni Fund. Prior to forming Pine Brook, Newman was vice chairman of Warburg Pincus, LLC, where he developed the energy and financial services businesses and led several other investing practices. He also spent 10 years in investment banking at Morgan Stanley &amp; Co., Incorporated, before joining Warburg Pincus.<\/p>\r\n\r\n<p>Newman earned his BA and MBA in economics from Yale University and his PhD in business economics from Harvard University.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 16 -->\r\n\t\r\n\t\r\n<!-- Person 17 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Frederik Paulsen, PhD<\/h2>\r\n<p class=\"bot-title\">Chairman Emeritus<br>\r\n<span style=\"font-weight: normal;\">Ferring Group<br>\r\nSwitzerland<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Paulsen-150x200-1.jpg\" alt=\"Frederik Paulsen\">\r\n\r\n<p>Frederik Paulsen has served on Salk\u2019s Board of Trustees since 2005. He is a Swedish businessman and explorer. In July 2021, Paulsen became chairman emeritus of Ferring Pharmaceuticals after serving as chairman of the board since 1988. Ferring Pharmaceuticals, which he joined in 1976, is a leader in reproductive medicine, gastroenterology, and urology.<\/p>\r\n\r\n<p>Paulsen is known for his interest in polar exploration, being a founding member of the Swiss Polar Institute and chairman of the University of the Arctic (UArctic). Paulsen maintains support for a diverse range of philanthropic activities in culture, science, education, and research, from Europe and the US to the remote island of South Georgia and the Kingdom of Bhutan. As founder of the Museum Kunst der Westk\u00fcste (Museum of West Coast Art) in Alkersum, Germany, Paulsen has supported the economy and heritage of the Island of his ancestors, F\u00f6hr. He is also a founding member of the South Georgia Heritage Trust in Scotland and has substantially contributed to the Salk Institute in La Jolla, California, as well as to the Kingdom of Bhutan\u2019s Royal Textile Academy.<\/p>\r\n\r\n<p>His accolades include being named an Officer of the Most Excellent Order of the British Empire (OBE) and a Knight of the Order of St. John by Queen Elizabeth II. He studied chemistry at Christian-Albrecht University in Kiel, Germany, and Business Administration at the University of Lund, Sweden. Paulsen earned his PhD from the \u00c9cole des Hautes \u00c9tudes en Sciences Sociales in Paris.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 17 -->\r\n\t\r\n\t\r\n<!-- Person 18 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Markus Reinhard<\/h2>\r\n<p class=\"bot-title\">Managing Director<br>\r\n<span style=\"font-weight: normal;\">NOMIS Foundation<br>\r\nSwitzerland<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Marcus-BOT.png\" alt=\"Markus Reinhard \">\r\n\r\n<p>Markus Reinhard has served on Salk\u2019s Board of Trustees since 2015. He is currently chair of the People &amp; Culture Committee. He is the managing director of the NOMIS Foundation based in Zurich, Switzerland since 2015. The NOMIS Foundation promotes and funds highly innovative basic research in the sciences, social sciences, and the humanities with a strong emphasis to enabling insight-driven science across all disciplines, focusing on researchers who put forth bold new ideas, exhibit a pioneering spirit, and seek to inspire the world around them. Prior to his NOMIS appointment, he spent more than 25 years as a human resources and communications executive in international business.<\/p>\r\n\r\n<p>He worked in the healthcare industry for more than 15 years and has served as senior vice president and head of global human resources for Baxter International\u2019s former Global BioScience Division (Baxalta). He lived and worked in Chicago (US) and Vienna (Austria) before moving to Zurich (Switzerland).<\/p>\r\n\r\n<p>Reinhard earned advanced degrees in clinical psychology, education sciences, and communications from the University of Vienna (Austria).<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 18 -->\r\n\r\n\r\n<!-- Person 19 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Eric Sagerman<\/h2>\r\n<p class=\"bot-title\">Strategic Advisor<br>\r\n<span style=\"font-weight: normal;\">California<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Sagerman-150x200-1.jpg\" alt=\"Eric Sagerman\">\r\n\r\n<p>Eric Sagerman has served on Salk\u2019s Board of Trustees since 2016. He is currently co-chair of the Investment Committee. He is a strategic advisor and director with experience across various industries, including financial services, technology, and healthcare.<\/p>\r\n\r\n<p>He was previously CEO and president of Universata. Previously, he served as managing director and head of strategy at Allianz Global Investors, following his role as managing director at Nicholas Applegate Capital Management. Sagerman began his career at American Express, where he became a senior vice president.<\/p>\r\n\r\n<p>He is currently co-chair of the Salk Institute Investment Committee and a member of the Salk Finance Committee.<\/p>\r\n\r\n<p>Sagerman earned his BA in economics from Tufts University and an MBA from the Amos Tuck School at Dartmouth College.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 19 -->\r\n\t\r\n\r\n<!-- Person 20 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Mary Jane Salk<\/h2>\r\n<p class=\"bot-title\">Author and Philanthropist<br>\r\n<span style=\"font-weight: normal;\">New York<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/MJ-Salk-150x200-1.jpg\" alt=\"Mary Jane Salk\">\r\n\r\n<p>Mary Jane Salk has served on Salk\u2019s Board of Trustees since 2014. She was for many years editor of the women\u2019s magazine group of Magazine Management, then parent company of Marvel Comics. She was editorial director of Transworld Feature Syndicate, an international magazine consortium.<\/p>\r\n\r\n<p>She is the author of five in a series of young adult books for Chelsea House Publishers; author of a work of fiction, <em>Kingdoms<\/em>; and associate producer of the feature films <em>Goodbye, New York<\/em> und <em>Forever Lulu<\/em>.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 20 -->\r\n\r\n\r\n<!-- Person 21 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Timothy M. Schoen<\/h2>\r\n<p class=\"bot-title\">CEO<br>\r\n<span style=\"font-weight: normal;\">BioMed Realty<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Schoen-150x200-1.jpg\" alt=\"Timothy M. Schoen\">\r\n\r\n<p>Timothy M. Schoen has served on Salk\u2019s Board of Trustees since 2019. He is currently chair of the Finance Committee. He is the CEO of BioMed Realty, having joined the company as president in May 2016. In this role, he leads strategic initiatives to advance the firm\u2019s mission of providing real estate solutions for the life sciences sector.<\/p>\r\n\r\n<p>Before BioMed Realty, Schoen served as executive vice president and chief financial officer of HCP, Inc. from May 2011 to May 2016. During his tenure at HCP, he held various executive roles, including executive vice president of Life Science &amp; Investment Management and senior vice president of Investment Management. Prior to HCP, he spent nine years as vice president of corporate finance at Kilroy Realty Corporation, where he honed his expertise in real estate finance and investment.<\/p>\r\n\r\n<p>Schoen earned his BS in finance and international business from Minnesota State University and his MBA from the University of California, Irvine.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 21 -->\r\n\r\n\r\n<!-- Person 22 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Andrew \u201cDrew\u201d Senyei<\/h2>\r\n<p class=\"bot-title\">Venture Capitalist and Inventor<br>\r\n<span style=\"font-weight: normal;\">California<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2025\/12\/25-bot-senyei.jpg\" alt=\"Drew Senyei\">\r\n\r\n<p>Andrew \u201cDrew\u201d Senyei has served on Salk\u2019s Board of Trustees since 2025. He cofounded Enterprise Partners Venture Capital in 1986, an investment firm focused on early-stage technologies and services in healthcare, biotechnology, and information technology. He continues to be active in early-stage technology investing and is now a senior advisor to private equity fund Healthpoint Capital.<\/p>\r\n\r\n<p>Senyei invented the first FDA-approved test to predict preterm birth, which has now been used by more than 8 million women worldwide. He was the founding investor of Nuvasive, one of the largest orthopedic companies in the US, until it was acquired by Globus Medical in 2023. Senyei also served as executive chairman of NeoSeq Ltd., a company specializing in advanced genetic testing for cancer and other diseases.<\/p>\r\n\r\n<p>Senyei earned his bachelor\u2019s degree at Occidental College, his medical degree at Northwestern University, and completed his residency training at the University of California, Irvine.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 22 -->\r\n\t\r\n\t\r\n<!-- Person 23 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Haeyoung Kong Tang, PhD<\/h2>\r\n<p class=\"bot-title\"> Philanthropist<br>\r\n<span style=\"font-weight: normal;\">California<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Tang-150x200-1.jpg\" alt=\"Haeyoung Kong Tang\">\r\n\r\n<p>Haeyoung Kong Tang has served on Salk\u2019s Board of Trustees since 2015. She is currently vice chair of the Nominating &amp; Governance Committee. She is a philanthropist. Through her foundation, Tang supports educational, environmental, and community causes. As a former research scientist, she has co-authored scientific articles and holds patents related to her earlier discoveries.<\/p>\r\n\r\n<p>Tang earned her BS in chemistry at Duke University and her PhD in pharmacology at the University of Pennsylvania.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 23 -->\r\n\t\r\n\r\n<!-- Person 24 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Dan Tierney<\/h2>\r\n<p class=\"bot-title\">President<br>\r\n<span style=\"font-weight: normal;\">Wicklow Capital Inc.<br>\r\nIllinois<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<p>Dan Tierney has served on Salk\u2019s Board of Trustees since 2015. In 1999, he co-founded GETCO-Global Electronic Trading Company, one of the world\u2019s first automated market-making firms. In 2012, Tierney started Wicklow Capital, his family office. Wicklow Capital engages in a combination of venture capital investing and venture philanthropy. The core focus is ABCD\u2014 AI, Blockchain, Climate, and Democracy.<\/p>\r\n\r\n<p>Tierney earned his BS in economics and finance from Bentley University in Waltham, Massachusetts, yet found his minor in philosophy to ultimately be of greater value.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 24 -->\r\n\t\r\n\t\r\n<!-- Person 25 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Horacio Valeiras<\/h2>\r\n<p class=\"bot-title\">CEO and Partner<br>\r\n<span style=\"font-weight: normal;\">Frontier Global Partners<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2025\/05\/25-bot-valeiras.jpg\" alt=\"Haeyoung Kong Tang\">\r\n\r\n<p>Horacio Valeiras has served on Salk\u2019s Board of Trustees since 2025. He is CEO of Frontier Global Partners. He previously held investment roles at Anderson &amp; Sherrerd and later acted as managing director of Morgan Stanley Investment Management. Valeiras went on to serve as chief investment officer at Allianz Global Investors in 2002, and later founded HAV Capital LLC, which merged into his current CEO role at Frontier Global Partners.<\/p>\r\n\r\n<p>Valeiras earned his bachelor\u2019s degree in chemical engineering at Virginia Tech and his master\u2019s degree at MIT. While in Boston, he began taking business classes and quickly realized the discipline and analytical skills he developed as an engineer were also powerful business skills. This inspired his post-graduation pivot from chemicals research at Chevron to earning his MBA at UC Berkeley.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 25 -->\r\n\t\r\n\r\n<!-- Person 26 -->\r\n<div class=\"accordion\" onclick=\"toggleAccordion(this)\">\r\n<div class=\"accordion-header\">\r\n<div style=\"display: flex; align-items: center;\">\r\n<div class=\"entry\">\r\n<h2>Irving Weissman, MD<\/h2>\r\n<p class=\"bot-title\">Professor<br>\r\n<span style=\"font-weight: normal;\">Stanford University<br>\r\nCalifornia<\/span><\/p>\r\n<\/div>\r\n<\/div>\r\n<span class=\"toggle-icon\">\u25bc<\/span>\r\n<\/div>\r\n\r\n<div class=\"accordion-content\">\r\n<img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Weissman-150x200-1.jpg\" alt=\"Irving Weissman\">\r\n\r\n<p>Irving Weissman is the founding director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University School of Medicine, where he is a professor of Pathology and Developmental Biology. He leads a research group focused on stem cell biology and regenerative medicine, training hundreds of students and authoring more than 950 scientific articles.<\/p>\r\n\r\n<p>An expert in hematopoiesis and leukemia, Weissman&#8217;s lab was the first to identify and isolate blood-forming stem cells from mice. He discovered human hematopoietic stem cells (HSCs), demonstrating their potential to regenerate blood formation in cancer patients. His work has included clinical trials for stem cell treatments in eye, brain, and spinal cord diseases, and he has explored CD47 as a cancer therapeutic.<\/p>\r\n\r\n<p>Weissman has received numerous awards and is an elected member of prestigious organizations, including the National Academy of Sciences. He served as president of the American Association of Immunologists and the International Society of Stem Cell Research. He has founded several companies focused on stem cell therapies and has been involved in the scientific advisory boards of major biotechnology firms.<\/p>\r\n\r\n<p>Weissman earned his BS from Montana State College and his MD in medicine from Stanford University.<\/p>\r\n<\/div>\r\n<\/div>\r\n<!-- End Person 26 -->\r\n \r\n<\/div>\r\n\r\n<script>\r\n    function toggleAccordion(element) {\r\n        \/\/ Collapse other active accordions\r\n        document.querySelectorAll('.accordion.active').forEach((accordion) => {\r\n            if (accordion !== element) {\r\n                accordion.classList.remove('active');\r\n                accordion.querySelector('.accordion-content').style.display = 'none';\r\n            }\r\n        });\r\n\r\n        \/\/ Toggle the clicked accordion\r\n        element.classList.toggle('active');\r\n        let content = element.querySelector('.accordion-content');\r\n        content.style.display = content.style.display === 'block' ? 'none' : 'block';\r\n    }\r\n<\/script>","protected":false},"excerpt":{"rendered":"<style>\r\n\t.centered-bio-wrapper {\r\n\t\tdisplay: flex;\r\n\t\tjustify-content: center;\r\n\t\tmargin-bottom: 20px;\r\n\t}\r\n\r\n\t.centered-bio {\r\n\t\twidth: 48%; \/* Same width as the columns *\/\r\n\t}\r\n\r\n\t\t.bot-title {\r\n\t\t\tfont-weight: bold;\r\n\t\t}\r\n\r\n\t.accordion-container {\r\n\t\tdisplay: grid;\r\n\t\tgrid-template-columns: 1fr 1fr; \/* Two columns *\/\r\n\t\tgap: 20px;\r\n\t}\r\n\t\r\n    .accordion {\r\n       \r\n        border: 1px solid #ddd;\r\n        margin-bottom: 10px;\r\n        cursor: pointer;\r\n        transition: background-color 0.3s;\r\n    }\r\n\r\n    .accordion:hover {\r\n        background-color: #fff;\r\n    }\r\n\r\n    .accordion-header {\r\n        padding: 15px;\r\n        display: flex;\r\n        justify-content: space-between;\r\n        align-items: center;\r\n    }\r\n\r\n    .accordion-header h3 {\r\n        margin: 0;\r\n        font-size: 1.1em;\r\n        color: #333;\r\n    }\r\n\r\n    .accordion-header img {\r\n        width: 50px;\r\n        height: 50px;\r\n        border-radius: 50%;\r\n        object-fit: cover;\r\n        margin-right: 15px;\r\n    }\r\n\r\n    .accordion-content {\r\n        display: none;\r\n        padding: 20px;\r\n        border-top: 1px solid #ddd;\r\n        background-color: #f8f8f8;\r\n        overflow: hidden;\r\n        transition: max-height 0.3s ease;\r\n    }\r\n\r\n    .accordion-content img {\r\n        float: left;\r\n        width: 150px;\r\n        height: 200px;\r\n        object-fit: cover;\r\n        margin-right: 20px;\r\n    }\r\n\r\n    .accordion-content p {\r\n       \r\n        color: #555;\r\n    }\r\n\r\n    .accordion-content::after {\r\n        content: \"\";\r\n        display: table;\r\n        clear: both;\r\n    }\r\n\r\n    .toggle-icon {\r\n        font-size: 1.5em;\r\n        color: #333;\r\n        transition: transform 0.3s;\r\n    }\r\n\r\n    .active .toggle-icon {\r\n        transform: rotate(180deg);\r\n    }\r\n<\/style>\r\n\r\n\r\n<p>The Board of Trustees is composed of proven leaders from the world&#8217;s business and non-profit communities who bring a range of skills and perspectives to the Institute. They are committed to science, innovation, high-quality research and supporting the Institute&#8217;s mission. Trustees are charged with monitoring Institute operations to ensure the organization fulfills its scientific and training efforts, while operating in a financially responsible manner.\r\n<\/p>","protected":false},"author":91,"featured_media":0,"parent":41622,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"folder":[562],"class_list":["post-53370","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Board of Trustees - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/de\/people\/salk-board-of-trustees\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Board of Trustees - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"The Board of Trustees is composed of proven leaders from the world&#8217;s business and non-profit communities who bring a range of skills and perspectives to the Institute. They are committed to science, innovation, high-quality research and supporting the Institute&#8217;s mission. Trustees are charged with monitoring Institute operations to ensure the organization fulfills its scientific and training efforts, while operating in a financially responsible manner.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/de\/people\/salk-board-of-trustees\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T19:30:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Marna-BOT.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"25 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/people\\\/salk-board-of-trustees\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/people\\\/salk-board-of-trustees\\\/\",\"name\":\"Board of Trustees - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/people\\\/salk-board-of-trustees\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/people\\\/salk-board-of-trustees\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Marna-BOT.png\",\"datePublished\":\"2025-05-16T21:06:36+00:00\",\"dateModified\":\"2026-03-05T19:30:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/people\\\/salk-board-of-trustees\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/people\\\/salk-board-of-trustees\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/people\\\/salk-board-of-trustees\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Marna-BOT.png\",\"contentUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Marna-BOT.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/people\\\/salk-board-of-trustees\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"People\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/people\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Board of Trustees\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Board of Trustees - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/de\/people\/salk-board-of-trustees\/","og_locale":"de_DE","og_type":"article","og_title":"Board of Trustees - Salk Institute for Biological Studies","og_description":"The Board of Trustees is composed of proven leaders from the world&#8217;s business and non-profit communities who bring a range of skills and perspectives to the Institute. They are committed to science, innovation, high-quality research and supporting the Institute&#8217;s mission. Trustees are charged with monitoring Institute operations to ensure the organization fulfills its scientific and training efforts, while operating in a financially responsible manner.","og_url":"https:\/\/www.salk.edu\/de\/people\/salk-board-of-trustees\/","og_site_name":"Salk Institute for Biological Studies","article_modified_time":"2026-03-05T19:30:16+00:00","og_image":[{"url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Marna-BOT.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"25 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/people\/salk-board-of-trustees\/","url":"https:\/\/www.salk.edu\/people\/salk-board-of-trustees\/","name":"Board of Trustees - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.salk.edu\/people\/salk-board-of-trustees\/#primaryimage"},"image":{"@id":"https:\/\/www.salk.edu\/people\/salk-board-of-trustees\/#primaryimage"},"thumbnailUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Marna-BOT.png","datePublished":"2025-05-16T21:06:36+00:00","dateModified":"2026-03-05T19:30:16+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/people\/salk-board-of-trustees\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/people\/salk-board-of-trustees\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.salk.edu\/people\/salk-board-of-trustees\/#primaryimage","url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Marna-BOT.png","contentUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2024\/11\/Marna-BOT.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/people\/salk-board-of-trustees\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"People","item":"https:\/\/www.salk.edu\/people\/"},{"@type":"ListItem","position":3,"name":"Board of Trustees"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"Salk-Institut f\u00fcr biologische Studien","description":"Die Macht der Wissenschaft","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"Salk-Institut f\u00fcr biologische Studien","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"hero":"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/07\/20220831-551A8886-web.jpg","line_1":"Leadership","line_2":"Board of Trustees","poster_quote":"","gallery":false,"salk_custom_body_class":"","secondary_navigation":"<div class=\"menu-leadership-container\"><ul id=\"menu-leadership\" class=\"menu\"><li class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-579\"><a href=\"https:\/\/www.salk.edu\/de\/people\/management-team\/\">Executive Leadership Team<\/a><\/li>\n<li class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-53412\"><a href=\"https:\/\/www.salk.edu\/de\/people\/salk-board-of-trustees\/\">Board of Trustees<\/a><\/li>\n<li class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-722\"><a href=\"https:\/\/www.salk.edu\/de\/people\/academic-council\/\">Academic Council<\/a><\/li>\n<li class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-721\"><a href=\"https:\/\/www.salk.edu\/de\/people\/administration\/\">Administration<\/a><\/li>\n<\/ul><\/div>"},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/pages\/53370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/users\/91"}],"replies":[{"embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/comments?post=53370"}],"version-history":[{"count":24,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/pages\/53370\/revisions"}],"predecessor-version":[{"id":56145,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/pages\/53370\/revisions\/56145"}],"up":[{"embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/pages\/41622"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/media?parent=53370"}],"wp:term":[{"taxonomy":"folder","embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/folder?post=53370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}